Opko Health - Der nächste Blockbuster (Seite 303)
eröffnet am 10.12.13 19:42:20 von
neuester Beitrag 07.05.24 22:55:13 von
neuester Beitrag 07.05.24 22:55:13 von
Beiträge: 3.051
ID: 1.189.336
ID: 1.189.336
Aufrufe heute: 0
Gesamt: 261.397
Gesamt: 261.397
Aktive User: 0
ISIN: US68375N1037 · WKN: A0MUUJ · Symbol: XCY
1,3200
USD
+1,54 %
+0,0200 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
| TitelBeiträge |
|---|
07.05.24 · globenewswire  |
03.05.24 · globenewswire |
05.03.24 · globenewswire |
27.02.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,0000 | +42,18 | |
| 2,0600 | +24,85 | |
| 5,6600 | +16,70 | |
| 8,0500 | +16,50 | |
| 1,1600 | +16,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7200 | -15,29 | |
| 0,6460 | -19,25 | |
| 0,5801 | -19,43 | |
| 4,4900 | -30,92 | |
| 19,860 | -65,04 |
Beitrag zu dieser Diskussion schreiben
Feedback
OPKO Health's (OPK) CEO Phillip Frost on Q3 2017 Results - Earnings Call Transcript
Nov. 8, 2017 11:11 PM ET
|
| About: OPKO Health, Inc. (OPK)
Q3: 11-05-17 Earnings Summary
• Press Release
• 10-Q
• News
EPS of $-0.08 misses by $-0.03
Revenue of $263.5M (- 11.6% Y/Y) misses by $-55.93M
OPKO Health, Inc. (NYSEMKT:OPK)
Q3 2017 Earnings Conference Call
November 8, 2017 4:30 PM ET
Executives
Anne Marie Fields - Senior Vice President, LHA
Phillip Frost - Chairman and Chief Executive Officer
Steven Rubin - Executive Vice President, Administration
Adam Logal - Vice President and Chief Financial Officer
David Okrongly - President of Diagnostics Business Unit
Thomas Nusbickel - Chief Commercial Officer
Analysts
Louise Chen - Cantor Fitzgerald
Christian Trigani - Jefferies
Kevin DeGeeter - Ladenburg
Eric Joseph - JPMorgan
I-Eh Jen - Laidlaw & Company
Mike Petusky - Barrington Research
Brandon Couillard - Jefferies
Nachlesen kann man diesen Conference Call hier:
https://seekingalpha.com/article/4122661-opko-healths-opk-ce…
nachdem die Aktie gestern 2% an der Nasdaq auf 6,45 US-$ verlor...
Nov. 8, 2017 11:11 PM ET
|
| About: OPKO Health, Inc. (OPK)
Q3: 11-05-17 Earnings Summary
• Press Release
• 10-Q
• News
EPS of $-0.08 misses by $-0.03
Revenue of $263.5M (- 11.6% Y/Y) misses by $-55.93M
OPKO Health, Inc. (NYSEMKT:OPK)
Q3 2017 Earnings Conference Call
November 8, 2017 4:30 PM ET
Executives
Anne Marie Fields - Senior Vice President, LHA
Phillip Frost - Chairman and Chief Executive Officer
Steven Rubin - Executive Vice President, Administration
Adam Logal - Vice President and Chief Financial Officer
David Okrongly - President of Diagnostics Business Unit
Thomas Nusbickel - Chief Commercial Officer
Analysts
Louise Chen - Cantor Fitzgerald
Christian Trigani - Jefferies
Kevin DeGeeter - Ladenburg
Eric Joseph - JPMorgan
I-Eh Jen - Laidlaw & Company
Mike Petusky - Barrington Research
Brandon Couillard - Jefferies
Nachlesen kann man diesen Conference Call hier:
https://seekingalpha.com/article/4122661-opko-healths-opk-ce…
nachdem die Aktie gestern 2% an der Nasdaq auf 6,45 US-$ verlor...
Es gibt einen neuen Lizenzvertrag, wie hier zu finden war:
https://www.streetinsider.com/Corporate+News//OPKO+Health+%2…
OPKO Health (OPK) Licensee TESARO (TSRO) Granted FDA Approval of VARUBI
October 26, 2017 4:57 PM EDT
OPK Hot Sheet
Price: $6.84 +0.44%
Overall Analyst Rating: BUY ( Up)
Revenue Growth %: -12.0%
OPKO Health, Inc. (NASDAQ: OPK) announces that its licensee, TESARO, Inc. (NASDAQ: TSRO), received U.S. Food and Drug Administration (FDA) approval for VARUBI® (rolapitant) IV in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Delayed nausea and vomiting can occur anytime between 25 and 120 hours following chemotherapy, and is often extremely debilitating.
TESARO licensed exclusive rights for the development, manufacture, commercialization, and distribution of VARUBI (rolapitant) from OPKO Health in December 2010. TESARO previously launched an oral version of VARUBI in November 2015. OPKO Health will receive tiered double-digit royalties on sales of VARUBI IV. In addition, OPKO Health is eligible to receive additional commercial milestone payments of up to $85 million upon achievement of certain sales thresholds. TESARO is expected to launch VARUBI IV in November 2017.
“We are especially pleased that our partner, TESARO, has received FDA approval for VARUBI IV. This is particularly important as IV treatments for chemotherapy induced nausea and vomiting account for 90% of the market. We look forward to TESARO’s continued success in commercializing the VARUBI product line,” said Philip Frost, M.D., Chairman and Chief Executive Officer of OPKO Health.
About VARUBI
VARUBI is a highly selective and competitive antagonist of human substance P/neurokinin 1 (NK-1) receptors, which play an important role in the delayed phase of chemotherapy induced nausea and vomiting (CINV). With a long plasma half-life of approximately seven days, a single dose of VARUBI, as part of an antiemetic regimen, significantly improved complete response (CR) rates in the delayed phase of CINV. Results from three Phase 3 trials of VARUBI oral tablets demonstrated a significant reduction in episodes of vomiting or use of rescue medication during the 25- to 120-hour period following administration of highly emetogenic and moderately emetogenic chemotherapy regimens. In addition, patients who received VARUBI reported experiencing less nausea that interfered with normal daily life and fewer episodes of vomiting or retching over multiple cycles of chemotherapy. Results from a bioequivalence trial demonstrated comparability of the IV and oral formulations of VARUBI.
VARUBI is available by prescription only. Please see full prescribing information, including additional important safety information, available at www.varubirx.com.
https://www.streetinsider.com/Corporate+News//OPKO+Health+%2…
OPKO Health (OPK) Licensee TESARO (TSRO) Granted FDA Approval of VARUBI
October 26, 2017 4:57 PM EDT
OPK Hot Sheet
Price: $6.84 +0.44%
Overall Analyst Rating: BUY ( Up)
Revenue Growth %: -12.0%
OPKO Health, Inc. (NASDAQ: OPK) announces that its licensee, TESARO, Inc. (NASDAQ: TSRO), received U.S. Food and Drug Administration (FDA) approval for VARUBI® (rolapitant) IV in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Delayed nausea and vomiting can occur anytime between 25 and 120 hours following chemotherapy, and is often extremely debilitating.
TESARO licensed exclusive rights for the development, manufacture, commercialization, and distribution of VARUBI (rolapitant) from OPKO Health in December 2010. TESARO previously launched an oral version of VARUBI in November 2015. OPKO Health will receive tiered double-digit royalties on sales of VARUBI IV. In addition, OPKO Health is eligible to receive additional commercial milestone payments of up to $85 million upon achievement of certain sales thresholds. TESARO is expected to launch VARUBI IV in November 2017.
“We are especially pleased that our partner, TESARO, has received FDA approval for VARUBI IV. This is particularly important as IV treatments for chemotherapy induced nausea and vomiting account for 90% of the market. We look forward to TESARO’s continued success in commercializing the VARUBI product line,” said Philip Frost, M.D., Chairman and Chief Executive Officer of OPKO Health.
About VARUBI
VARUBI is a highly selective and competitive antagonist of human substance P/neurokinin 1 (NK-1) receptors, which play an important role in the delayed phase of chemotherapy induced nausea and vomiting (CINV). With a long plasma half-life of approximately seven days, a single dose of VARUBI, as part of an antiemetic regimen, significantly improved complete response (CR) rates in the delayed phase of CINV. Results from three Phase 3 trials of VARUBI oral tablets demonstrated a significant reduction in episodes of vomiting or use of rescue medication during the 25- to 120-hour period following administration of highly emetogenic and moderately emetogenic chemotherapy regimens. In addition, patients who received VARUBI reported experiencing less nausea that interfered with normal daily life and fewer episodes of vomiting or retching over multiple cycles of chemotherapy. Results from a bioequivalence trial demonstrated comparability of the IV and oral formulations of VARUBI.
VARUBI is available by prescription only. Please see full prescribing information, including additional important safety information, available at www.varubirx.com.
Kursentwicklung sieht gut aus. Getragen von erhöhtem Volumen:
=> USD6 sind wahrscheinlich nun Vergangenheit.
=> USD6 sind wahrscheinlich nun Vergangenheit.
Die Insiderkäufe halten an: nochmals 40.000 OPKO Health Inc. - Aktien (= 0,007%) für den Frost Nevada Investment Trust, wie heute der SEC gemeldet.
http://investor.opko.com/secfiling.cfm?filingid=1209191-17-5…
http://investor.opko.com/secfiling.cfm?filingid=1209191-17-5…
Antwort auf Beitrag Nr.: 55.754.307 von vonHS am 15.09.17 17:47:56Der Frost Nevada Investment Trust des CEO Phillip Frost hat am Freitag nochmals 80.000 (= 0,014%) Aktien nachgekauft und verfügt jetzt mit den Käufen an diesen beiden Tagen über 340.000 (= 0,061%) Aktien.
Auch der Vizepräsident und CFO von Opko, Adam Logal, kaufte am Freitag für etwas mehr als 10.000 US-$ 1.500 (= 0,0027%) Aktien und verfügt jetzt über 162.793 (= 0,029%) Aktien.
Trotzdem geht es mit dem Kurs (in Frankfurt) auch heute weiter abwärts. Wo liegt der Boden dieser Aktie?
Auch der Vizepräsident und CFO von Opko, Adam Logal, kaufte am Freitag für etwas mehr als 10.000 US-$ 1.500 (= 0,0027%) Aktien und verfügt jetzt über 162.793 (= 0,029%) Aktien.
Trotzdem geht es mit dem Kurs (in Frankfurt) auch heute weiter abwärts. Wo liegt der Boden dieser Aktie?
Trading Spotlight
Den gestrigen Kursrutsch hat der CEO für eine seiner Firmen (hier: Frost Nevada Investments Trust) genutzt, und schnell mal 260.000 Aktien (= ca. 0,05%) eingesammelt, wie der SEC-Meldung von heute zu entnehmen ist.
http://investor.opko.com/secfiling.cfm?filingid=1209191-17-5…
Wenn ich das SEC-Dokument richtig verstehe, geht daraus hervor, dass auch weitere Frost-Firmen Aktien wie folgt besitzen:
- Frost Gamma Investments Trust: 164.234.443 (= 29,33%)
- The Frost Group, LLC: 20.091.062 (= 3,59%)
und der CEO Dr. Phillip Frost selbst weitere:
- Eigenbesitz: 3.068.951 (= 0,55%)
So dass er über etwa ein Drittel aller Opko-Aktien direkt informiert ist.
http://investor.opko.com/secfiling.cfm?filingid=1209191-17-5…
Wenn ich das SEC-Dokument richtig verstehe, geht daraus hervor, dass auch weitere Frost-Firmen Aktien wie folgt besitzen:
- Frost Gamma Investments Trust: 164.234.443 (= 29,33%)
- The Frost Group, LLC: 20.091.062 (= 3,59%)
und der CEO Dr. Phillip Frost selbst weitere:
- Eigenbesitz: 3.068.951 (= 0,55%)
So dass er über etwa ein Drittel aller Opko-Aktien direkt informiert ist.
An der Nasdaq geht es heute zu Handelsbeginn gleich fast um 7,5 % nach unten. Das war heute als Auslöser dafür geschehen:
"Opko Health (NYSEMKT:OPK) downgraded to Neutral by JPMorgan"
"Opko Health (NYSEMKT:OPK) downgraded to Neutral by JPMorgan"
Heute wurde eine neue Firmenpräsentation (auf englisch) veröffentlicht:
http://investor.opko.com/secfiling.cfm?filingid=1193125-17-2…
http://investor.opko.com/secfiling.cfm?filingid=1193125-17-2…
Nachdem sich der Kurs seit dem Hoch von Mitte Dezember 2016 dieses Jahr schon mehr als halbierte, glaubt der 80jährige Investmentstratege Dr. Phil Frost an sein seit 2007 als CEO geführtes Unternehmen und hatte im März 12.200 Stücke
http://www.reuters.com/article/brief-ceo-phillip-frost-repor…
im Mai 10.000 Stücke:
http://www.reuters.com/article/brief-opko-health-ceo-reports…
und weitere 9.200 Stücke:
http://www.reuters.com/article/brief-opko-health-ceo-phillip…
sowie im Juli 50.000 Stücke
http://www.reuters.com/article/brief-opko-health-ceo-phillip…
und auch im August nochmals 25.000 Stücke
http://www.reuters.com/article/brief-opko-health-ceo-phillip…
und gleich am Folgetag weitere 40.000 Stücke
http://www.reuters.com/article/brief-opko-health-ceo-phillip…
seiner Opko Health Inc. gekauft.
http://www.reuters.com/article/brief-ceo-phillip-frost-repor…
im Mai 10.000 Stücke:
http://www.reuters.com/article/brief-opko-health-ceo-reports…
und weitere 9.200 Stücke:
http://www.reuters.com/article/brief-opko-health-ceo-phillip…
sowie im Juli 50.000 Stücke
http://www.reuters.com/article/brief-opko-health-ceo-phillip…
und auch im August nochmals 25.000 Stücke
http://www.reuters.com/article/brief-opko-health-ceo-phillip…
und gleich am Folgetag weitere 40.000 Stücke
http://www.reuters.com/article/brief-opko-health-ceo-phillip…
seiner Opko Health Inc. gekauft.
.....nicht zu fassen, die machens schon vorher und wollen auf der ENDO was nochmal präsentieren?
Durchsuchen
